Cross-disease structural analysis ranking 9 disease areas by druggability evidence from the frozen v5.1 engine. All scores derived from real pipeline data — no simulated or predicted values.
Highest portfolio score — strongest structural evidence for druggability across targets.
Lowest portfolio score — structural evidence is weaker or more caveated.
| Disease | HIGH | MODERATE | LOW | Total | Avg Triage |
|---|---|---|---|---|---|
| Amyotrophic Lateral Sclerosis (ALS) | — | — | — | 0 | 0 |
| Prion Disease | — | — | — | 0 | 0 |
| COVID-19 | — | — | — | 0 | 0 |
| Asthma / COPD | — | — | — | 0 | 0 |
| Autoimmune / Inflammatory Disease | — | — | — | 0 | 0 |
| Breast Cancer (ER+ / HER2+) | — | — | — | 0 | 0 |
| Prostate Cancer (AR-driven) | — | — | — | 0 | 0 |
| Non-Small Cell Lung Cancer (EGFR+ / HER2+ / HER4+) | — | — | — | 0 | 0 |
| Chronic Pain / Neuropathy | — | — | — | 0 | 0 |
The library covers 0 distinct protein classes across 0 targets. Class diversity strengthens the engine's validation across different protein architectures — from GPCRs and cytokines to enzymes and structural proteins.
Portfolio scores combine lead target strength (35%), average triage across targets (25%), confidence quality (20%), coverage breadth (10%), and recurrence strength (10%). All metrics are derived from frozen v5.1 engine output — no manual adjustment, no therapeutic claims. Tractability rankings reflect structural evidence for druggability, not clinical probability of success. See Schema Documentation for complete field definitions and scoring methodology.